Background {#s1}
==========

Gitelman syndrome (GS) was first described in 1966 in a family characterised by hypokalaemia, hypomagnesaemia, hypocalciuria, metabolic alkalosis and hyper-reninemic hyperaldosteronism.[@R1] It is a rare autosomal recessive salt-losing tubulopathy with a prevalence estimated at approximately 1:40.000.[@R2] It is caused by mutations of *SLC12A3* gene that encodes the sodium chloride cotransporter (NCC) and magnesium channels in the thiazide-sensitive segment of the renal distal convoluted tubule.[@R3]

GS is usually diagnosed during adolescence or adulthood and the clinical spectrum is wide, ranging from asymptomatic to severe manifestations, such as episodes of paralysis, seizures or cardiac arrhythmias. Symptoms are related to electrolyte abnormalities; however, its severity does not correlate with the intensity of symptoms.[@R4] Moreover, the phenotype--genotype correlation is heterogeneous, since different phenotypes have been reported in family members presenting identical genetic defects.[@R5]

Hypocalciuria is a prominent feature in GS[@R1]; nevertheless, the total plasma calcium concentration has been reported to be normal.[@R1] Rarely, slight hypercalcaemia can occur in the course of GS due to dehydration-induced hyperproteinaemia.[@R6] Thereby, the presence of hypercalcaemia in the course of this disease should require further investigation.

Herein, we describe a rare case of GS associated with moderate to severe hypercalcaemia resulting in profound electrolyte imbalance. We also intend to report our apprehension in initial control of severe hypomagnesaemia in a patient with concomitant hypercalcaemia.

Case presentation {#s2}
=================

A 25-year-old Caucasian normotensive woman was admitted to the emergency department in June 2015 due to malaise, fatigue, myalgias, cramps, left hemiface and left upper arm paraesthesias. Head CT excluded intracranial lesions and blood tests revealed a low serum K^+^ of 2.9 mEq/L. She was referred to the Endocrinology clinic for evaluation of persistent hypokalaemia. She denied diarrhoea, abuse of diuretics, laxatives or 'natural supplements'. Concerning her family history, she has no siblings, her parents are non-consanguineous and healthy. Physical examination revealed depressed humour, normal body mass index (22 kg/m^2^), blood pressure 110/80 mm Hg, pulse rate 82 bpm, no stigmata of hypercortisolism and no focal neurological signs.

Investigations {#s3}
==============

The patient's laboratory findings are shown in [tables 1 and 2](#T1 T2){ref-type="table"}.

###### 

Laboratory results (July 2015)

                                                Normal range    
  --------------------------------------------- --------------- ------------
  Haemoglobin                                   12.9 g/L        12--15
  Leucocytes                                    11.90×10\^9/L   4.5--11
  Platelets                                     317×10\^9/L     150--450
  Glucose                                       69 mg/dL        60--100
  Urea                                          27 mg/dL        15--40
  Creatinine                                    0.57 mg/dL      0.57--1.11
  Glomerular filtration rate (GFR)\>60 mL/min                   
  Total proteins/albumin                        74 g/L          60--83
  Sodium (Na^+^)                                139 mEq/L       136--145
  Potassium (K^+^)                              2.7 mEq/L       3.5--5.1
  Chloride (Cl^-^)                              97 mEq/L        98--107
  Calcium (Ca^2+^)                              12 mg/dL        8.4--10.2
  Phosphorus (Pi)                               1.6 mg/dL       2.3--4.7
  Magnesium (Mg^2+)^                            0.71 mg/dL      1.6--2.6
  Total cholesterol                             254 mg/dL       \<190
  Aldosterone                                   47.1 ng/mL      4--31
  Active renin                                  374.7 uUI/mL    4.4--46.1

###### 

Laboratory results---24-hour urine (vol. 2300 mL)

           Normal range        
  -------- ------------------- ----------
  K^+^     84.7 mEq/24 hours   25--125
  Mg^2+^   143.1 mg/24 hours   73--122
  Ca^2+^   133 mg/24 hours     100--300
  Pi       1.1 g/24 hours      0.4--1.3

She presented with secondary hyperaldosteronism, renal wasting resulting in hypokalaemia and hypomagnesaemia. These laboratory findings associated with her normotensive profile favoured the diagnosis of GS. She was provided with a low dose of magnesium aspartate (500 mg/day) and oral potassium chloride progressively adjusted to 600 mg 4 id with improvement of the symptoms

The severity of hypercalcaemia did not seem to be justified by hypocalciuria of GS; furthermore, hypophosphataemia did not fit in this context. Additional tests revealed Ca^2+^ 11.8 mg/dL, Pi 1.9 mg/dL, PTH107.3 pg/mL (n.r. 14.8--83.1) and 25 OH vitamin D 20.4 ng/mL (n.r. 4.8--52.8) that were consistent with hypercalcaemia due to primary hyperparathyroidism (PHPT). Abdominal CT scan excluded renal lesions, such nephrolithiasis. Urinary metanephrines and pituitary function were normal. A cervical Doppler ultrasonography revealed a hypervascular, hypointense nodule with 19×9×9 mm at the inferior pole of left lobe of thyroid, between oesophagus and left carotid artery, compatible with parathyroid adenoma.

To confirm our clinical suspicion of GS, genetic study was required. The variant c.602--16G\>A and the variant c.2221G\>A (p.Gly741Arg), both in heterozygosity, were detected in *SLC12A3* gene ([figure 1](#F1){ref-type="fig"}). Genetic study of the parents was requested. The father presents the variant c.602--16G\>A and the mother the variant c.2221G\>A (p.Gly741Arg), in *SLC12A3* gene. The genetic study of the parents concluded that the variants found are in different alleles (*trans*), which reinforce their pathogenicity.

![Chromatographe of the sequence: above: representation of variant c.602--16G\>A; below: representation of variant c.2221G\>A (p.Gly741Arg), both detect in *SLC12A3* gene.](bcr-2017-223663f01){#F1}

The occurrence of PHPT in a young patient also justified DNA analysis of *HRPT2* and *MEN1* genes that were both normal in this case.

Treatment {#s4}
=========

An inferior left parathyroidectomy was performed and histological study confirmed the diagnosis of parathyroid adenoma.

Outcome and follow-up {#s5}
=====================

Serum Ca^2+^ and PTH normalised after surgery (Ca^2+^ 9.7 mg/dL, PTH 5 pg/mL and Pi 4.8 mg/dL). Hypocalciuria emerged and in 17 months of follow-up normocalcaemia persists ([table 3](#T3){ref-type="table"}). She maintained mild symptomatic hypokalaemia on oral KCl 600 mg 6id, thus spironolactone 100 mg/day was prescribed. During the last 6 months, medicated with spironolactone 100 mg/day, KCl 600 mg 2id, magnesium aspartate 1229.6 mg 4id, she presented serum K^+^ in the inferior limit of normal range. She maintains mild-to-moderate hypomagnesaemia which can be explained by *poor medication* adherence due to gastrointestinal intolerance ([table 3](#T3){ref-type="table"}). The patient keeps regular follow-up in our department with clinical and biochemical evaluation.

###### 

Laboratory tests (August 2016)

                              Normal range       
  --------------------------- ------------------ -------------
  Ca^2+^                      9.9 mg/dL          8.4--10.2
  24 hours urine Ca^2+^       \<53 mg/24 hours   100--300
  Pi                          2.9 mg/dL          2.3--4.7
  Mg^2+^                      1.09 mg/dL         1.6--2.6
  Parathyroid hormone (PTH)   14.9 pg/mL         14.76--83.1
  25 OH vitamin D             35 ng/mL           4.8--52.8
  Na^+^                       137 mEq/L          136--145
  K^+^                        3.6 mEq/L          3.5--5.1
  Cl^-^                       97 mEq/L           98--107

Discussion {#s6}
==========

GS is linked to inactivating mutations in the *SLC12A3* gene resulting in loss of function of the encoded NCC in the distal convoluted tubules. The clinical and biochemical picture of patients with GS resemble those who are on thiazide diuretics, given that the affected transporter is the exact target of thiazides.[@R4]

Despite clinical and biochemical similarities between patients with GS and those on thiazide diuretic therapy,[@R4] the presence of hypercalcaemia in the former group is unusual.[@R1] This fact can be explained by impaired calciotropic hormones due hypomagnesaemia in patients with GS.[@R6] Bianchetti *et al* demonstrated a blunted relationship between PTH, ionised calcium concentration and calcitriol in patients with GS providing evidence that these patients have a disturbed secretion of PTH.[@R6] Moreover in GS, normal levels of both plasma phosphate and urinary fractional phosphate excretion rule out PTH hyperfunction.[@R4]

We described a rare case of a young woman with GS presenting with hypercalcaemia due to PHPT. In PHPT, hypercalcaemia results from inappropriate hypersecretion of PTH from parathyroid gland(s). PTH increases tubular reabsorption of calcium in the kidney, stimulates release of skeletal calcium stores and upregulates 1α- hydroxylase resulting in increased 1,25-(OH)2D3 production and intestinal calcium absorption.[@R8]

The differential diagnosis between PHPT and familial hypocalciuric hypercalcaemia should be considered because the latter is a benign condition. In a patient with GS, this differentiation is difficult because of inherent hypocalciuria. In our patient, the diagnosis of PHTP was sustained by concomitant hypophosphataemia, high levels of PTH, unexpected 'normal calciuria' and the findings in neck ultrasonography. The normalisation of calcium values after parathyroidectomy also firms this hypothesis.

Genetic study of our patient detected the variant c.602--16G\>A and the variant c.2221G\>A (p.Gly741Arg), both in heterozygosity, in *SLC12A3* gene. The variant c.2221G\>A (p.Gly741Arg) was described in other patients with GS[@R9] and is found on dbSNP and ExAC databases with a global frequency of 0.040%. It is localised in a highly conserved residue and its functional impact was already studied. Thus, it should be considered a probably pathogenic variant. The variant c.602--16G\>A is described on the database of HGMD; as a disease-causing mutation,[@R11] it has been identified in two different families with GS, in *trans* with other pathogenic mutations. It is also described in dbSNP and ExAC databases with a frequency of 0.0016%. However, due to lack of functional studies confirming the splicing effect, this variant is considered of undetermined significance.

Genetic study of the parents revealed in the father the variant c.602--16G\>A and the mother the variant c.2221G\>A (p.Gly741Arg), in *SLC12A3* gene. The genetic study of the parents concluded that the variants found are in different alleles (*trans*), which reinforce their pathogenicity.

GS is a recessively inherited disease, with simple heterozygous relatives being asymptomatic. Nevertheless, there is a small percentage of affected individuals with only one mutant allele.[@R12] Since the expression of NCC may be influenced by epigenetic modifications and/or silent polymorphisms, this may lead to impaired function in simple heterozygous.[@R12] Screening of electrolyte abnormalities in parents was done and excluded a mild phenotype.

The combination of hypokalaemia, hypomagnesaemia and hypercalcaemia is uncommon but potentially lethal. To our knowledge, there is only one case reported in the literature. In our patient, initial severe hypomagnesaemia imposed carefully Mg^2+^ reposition, taking into account the risk of worsening hypercalcaemia and justified strictly electrolytic monitoring.

Molecular study added value since permits the screening of the parents and genetic counselling when pregnancy is desired.

###### Learning points

-   Gitelman syndrome (GS) is caused by mutations in the *SLC12A3* gene.

-   It is a rare autosomal recessive tubulopathy characterised by hypokalaemia, hypomagnesaemia, hypocalciuria, metabolic alkalosis and secondary hyperaldosteronism.

-   Hypercalcaemia due to hypocalciuria in these patients is extremely rare. This can be explained by impaired calciotropic hormones due to hypomagnesaemia observed in these patients.

-   The presence of hypercalcaemia in the course of GS requires further evaluation in order to exclude reversible causes of hypercalcaemia.
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